Tarsus Pharmaceuticals, Inc. Appoints Global Eye-Care Pioneer David E. I. Pyott To Board To Support XDEMVY Growth And Pipeline Expansion

Tarsus Pharmaceuticals, Inc. has announced the appointment of David E. I. Pyott, a highly respected global biopharmaceutical leader and former Chairman and CEO of Allergan, Inc., to its Board of Directors. According to Bobak Azamian, Chief Executive Officer and Chairman of the company, Mr. Pyott is among the most accomplished figures in the eye care industry, with a long history of transforming innovation into global commercial success. He noted that Mr. Pyott’s experience in building major industry franchises will play an important role as the company continues scaling XDEMVY, progresses pipeline development, and strengthens its position for long-term growth.

Mr. Pyott brings decades of leadership experience across global biopharmaceutical operations, including research and development, product innovation, and commercial execution. During his 17-year tenure at Allergan, he helped reshape the company from a smaller eye care-focused business generating roughly $1 billion in revenue into a global specialty pharmaceutical and medical device leader surpassing $7 billion in annual sales. His leadership guided the company through complex market environments while maintaining sustained growth and strong commercial momentum. His achievements earned him recognition as one of Harvard Business Review’s “100 Best Performing CEOs in the World.” Prior to his role at Allergan, he served as Head of the Novartis Nutrition Division and was a member of the Executive Committee of Novartis AG.

Mr. Pyott said he is pleased to join the Board as the company enters an important phase of its evolution. He emphasized that the organization has already built a strong foundation through its first commercial product and a promising development pipeline. He looks forward to collaborating with the Board and management team to support long-term value creation and foster further innovation in eye care and related therapeutic areas. In addition to his new role, Mr. Pyott currently serves on the Boards of Alnylam Pharmaceuticals and Pliant Therapeutics. His previous board experience includes serving on the Supervisory Board of Royal Philips and on the Board of Directors of BioMarin Pharmaceutical Inc..

Beyond his industry roles, Mr. Pyott is Chairman of the Governing Board of the London Business School, Vice President and co-founder of the Ophthalmology Foundation, and a Trustee of the California Institute of Technology. His academic background includes a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, an Honorary Degree in Medicine and a Master of Arts from the University of Edinburgh, and a Master of Business Administration from London Business School.